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Abstract
Anesthetic development has been a largely empirical process. Recently, we described a GABAergic mimetic model system
for anesthetic binding, based on apoferritin and an environment-sensitive fluorescent probe. Here, a competition assay
based on 1-aminoanthracene and apoferritin has been taken to a high throughput screening level, and validated using the
LOPAC
1280 library of drug-like compounds. A raw hit rate of ,15% was reduced through the use of computational filters to
yield an overall hit rate of ,1%. These hits were validated using isothermal titration calorimetry. The success of this initial
screen and computational triage provides feasibility to undergo a large scale campaign to discover novel general
anesthetics.
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Introduction
General anesthetics are used so commonly today that it is
difficult to escape life without having been exposed to them.
Despite their widespread use, no new general anesthetics have
been developed for over 30 years; all current development seems
targeted at pharmacokinetics as opposed to pharmacodynamics.
But this is not because these drugs have been optimized in terms of
specificity and side effect profile. Indeed, there is growing concern
that general anesthetics, especially the volatile ones, are associated
with cognitive effects that long outlast their residence in the brain
[1]. Thus, a need exists for new general anesthetics with improved
safety and specificity.
Previous development of general anesthetic drugs has always
been empirical, or based on non-specific physicochemical
properties, such as hydrophobicity. This is a result of not having
validated protein targets, or not having high resolution structures
of even putative targets, such as the GABAA receptor [2]. We have
recently reported that a soluble protein, apoferritin, mimics the
pharmacodynamic behavior of general anesthetic targets, and
more specifically the GABAA receptor [3,4]. Further, this protein
is readily crystallized and x-ray diffraction data of the anesthetic
protein complex resolved to high resolution [5]. This apoferritin
site binds specifically a wide range of general anesthetics, including
those that are inhaled and those that are injectable, and excludes
the non-immobilizers [6]. Therefore, we reasoned that this site
might serve as a platform for the first protein-based anesthetic
screening effort.
Screening efforts require a robust assay to report on binding or
an activity change in the target. Since our previous work with
apoferritin did not identify significant changes in apoferritin
activity on occupancy of the anesthetic site, we sought an assay to
report on occupancy alone. Most such assays employ fluorescence
competition, whereby a fluorescent reporter molecule is displaced
by compounds that also bind the site. A suitable candidate was
identified, and the binding and fluorescence properties of 1-
aminoanthracene (1-AMA) have recently been reported [3].
Further, we have shown that known general anesthetics (e.g.,
isoflurane and propofol) inhibit 1-AMA fluorescence (binding)
with IC50 values that closely approximates their KD obtained
through an independent method (isothermal titration calorimetry)
[3]. In this communication, we report on the miniaturization of
this assay and its validation in high throughput screening mode
using the LOPAC
1280 library of bioactive molecules.
Results
Assay Miniaturization
The previously-reported apoferritin-1-AMA binding assay was
miniaturized to 3 mL in 1,536-well plates. Baseline plate reads with
no added compound demonstrated robust signal and excellent
well-to-well uniformity in 1,536-well format (Figure 1). When 50%
saturated 1-AMA was complexed with 15 mM apoferritin, the
fluorescence increased 5.3-fold relative to free 1-AMA and the
associated Z’ factor [7] exceeded 0.85 (Figure 1). This result was
reproduced with two lots of horse-spleen apoferritin and upon
repeated testing. Robust signal was maintained when the
apoferritin concentration was lowered to 8 mM, in order to lower
the protein consumption. Figure 2 also demonstrates that the assay
reagents, as formulated at their screening concentrations, were
stable for over 24 hours: both the Z’ factor and the signal-to-
background ratio remained flat for the duration of the stability test.
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7150This excellent overnight stability coupled with robust assay
performance in 1,536-well plate format indicates that the assay
can be screened in an automated and unattended fashion.




1280 library was screened in qHTS mode [8] using
the above described 1-AMA/apoferritin assay, with library
compounds tested at seven concentrations in the range of
77 mM to 25 nM. The assay performance remained robust over
the course of the screen, with high Z’ factor maintained
throughout (Figure 3). Detailed results are provided in PubChem
(PubChem AID to be provided upon manuscript acceptance).
Figure 4 shows the cumulative library response in both 3D and pie
format, representing the activity distribution of compounds.
Concentration response curves (CRCs) were categorized into
three groups: inactive, active, inconclusive based on the quality of
the CRC and the maximum response of the compound. First,
inactive compounds have a maximum response of less than 3
sigma of the assay (10% inhibition for the LOPAC
1280 screen).
The qHTS yielded 910 compounds classified as inactive.
Additionally, 142 of the compounds displayed a signal increase
in the assay. These potential ‘activators’ were considered artifacts
and were also categorized as inactives. Among the compounds that
produced a signal decrease, CRCs with a partial or full response
and a maximum response greater than 60% inhibition were
categorized as active (5 compounds). An additional 201 com-
pounds had weaker inhibitory response, where the CRC r
2 was
less than 0.9 (noisy curves) or where the maximum response was
less than 6 sigma. These less reliable responses were nevertheless
Figure 1. Assay Miniaturization to 1,536-well format. Plate image (above) is shown with quantitation (below). Columns 1,2,5–48 are 15 mM
ApoF + 1-AMA, column 3,4 are free 1-AMA. 3 mL total volume, 15 min. incubation prior to fluorescence read. Top = raw ViewLux CCD image; bottom
= RFU data from CCD image demonstrating consistency. The Z’ factor and signal-to-background calculated from the first 128 wells of data (left four
columns) were 0.87 and 5.3, respectively.
doi:10.1371/journal.pone.0007150.g001
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actives. Finally, a small set of compounds (22) had curves that were
unclassified. These were noisy responses that showed some signal
change only at the highest concentration tested and were thus
considered to be inactive (listed as inconclusive in the pie chart of
Figure 4).
Filtering of Screening Hits
Most of the 206 inhibitors yielded incomplete CRCs. Physico-
chemical filtering of the 206 compounds eliminated all but 21
compounds. It is assumed that qHTS signal inhibition in the
eliminated compounds was largely the result of inner-filter or
aggregation effects. Finally, compounds that were classified as
‘‘inhibitors’’ based only on a single point of activity were
eliminated (2/21 compounds) to yield a final list of 19 active
compounds.
ITC
Eighteen of the 19 compounds could be obtained from the
primary suppliers for the low-throughput validation study. Of the
18 compounds, 11 yielded unambiguous evidence of a classic
exothermic binding interaction (see Figure 5A for an example),
and two provided endothermic relationships. Of the five giving
ambiguous data, or no heat signal at all (see Figure 5B for an
example), low compound solubility appears to be the dominant
reason. Figure 6 gives a list and structure of all the obtained
Figure 3. Robustness of screening assay: Z’ factor during the
experiment averaged 0.89.
doi:10.1371/journal.pone.0007150.g003
Figure 2. Assay stability. Bottles with free 1-AMA or complex were stored at 4uC, connected to a liquid dispenser at shown time points, and the
assay performed as described above. Fluorescence intensity, signal-to-background ratios (S:B) and Z’ factor were computed from 64 column 1,2 wells
(complex) and 64 column 3,4 wells (free 1-AMA).
doi:10.1371/journal.pone.0007150.g002
Figure 4. Cumulative results of the screen. Compounds are
grouped according to inhibitor (blue), activator (red), inactive (dark
grey) and inconclusive (light grey) categories.
doi:10.1371/journal.pone.0007150.g004
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qHTS and ITC. Considerable noise exists in the relationship
between the IC50 calculated from qHTS data and the KD
calculated from the enthalpograms (Figure 7), presumably because
the high protein (8 mM) and probe (15 mM) concentrations, and
limitations to compound solubility, produce incomplete curves in
the qHTS experiment. Nevertheless, the relationship between
qHTS and ITC measures of affinity is significant, and does not
deviate significantly from the line of identity.
Discussion
Despite decades of study, the mechanism of anesthetic action
has not emerged, and as a result, design of new anesthetic drugs
has been reduced to empiricism. There is general agreement,
however, that direct interactions with protein underlie the
desirable effects of anesthetics, lending hope that novel compounds
can be found. The problem has been the lack of validated,
structurally accessible targets on which to focus. The GABAA
receptor/ion channel, for example, is thought by many investiga-
tors to be an important anesthetic target [9], yet only homology
models based on a low resolution cryoEM structure of the
nicotinic acetylcholine receptor are available [10]. Further, there is
only a general idea of where the anesthetic site on this large
heteroligomer resides [2,11]. Thus, a surrogate approach, based
on another protein that displays pharmacodynamic mimicry [4,5],
was employed here. The assay method is based on a fluorophore
that binds the anesthetic cavity on apoferritin, shows a large
increase in fluorescence on binding, and is a general, GABAergic
anesthetic itself [3].
The number of raw hits obtained in this screen is large, but the
filtering based on known cavity characteristics [4,5], shows that
most are due to interactions other than competitive binding at the
anesthetic site. These interactions include fluorescence interfer-
ence and aggregation, although the latter is expected to enhance
signal rather than reduce because of partitioning of 1-AMA into
the compound micelle; indeed, we observed 142 such compounds
in the screen. Fluorescence interference will primarily be due to
inner-filter effect, whereby the compound absorbs the excitation or
emission wavelengths of 1-AMA. For example, compounds S-1693
and S-3066 were classified as inhibitors by qHTS, each producing
,30% inhibition at maximal concentrations (77 mM), but ITC
failed to provide convincing evidence of binding. This is likely due
to considerable absorbance at the excitation wavelength (340 nm).
Future assays will take advantage of the broad absorbance band of
1-AMA, and red-shift the excitation wavelength closer to 400 nm.
This should also have the advantage of better signal to noise ratios,
permitting decreased reagent consumption.
The simple filters used here take advantage of the fact that
apoferritin has a high (1.7 A ˚) resolution structure, the general
anesthetic binding site has been identified, and it is an enclosed
cavity, rather than a surface patch [5]. Thus, there are defined
limitations on the size and physiochemical character of compounds
which can be accommodated in this site. Further, because of the
stability of the apoferritin oligomer, this site is unlikely to undergo
significant ‘‘induced fit’’. We chose filter parameters broad enough
to capture novel compounds, but exclude those clearly outside the
range that could be accommodated by the apoferritin site. We
recognize that our filtering process is essentially a partial return to
empiricism, but we note that it retains the important element of
targeted protein binding. That the protein site is providing the
dominant selectivity, as opposed to the filters, is illustrated by the
fact that these filters alone select 176 of 910 inactive LOPAC
compounds. Figure 8 shows that while there is the expected
difference in mean hydrophobicity between screened inactive and
inhibitors, the overlap is large. This suggests that the 3 dimensional
interactions of compound atoms with those of the cavity lining, (e.g.,
the pharmacophore) have the largest influence on binding.
Figure 5. Typical ITC enthalpograms. LOPAC compound T-8543 shows clear exothermic binding behavior (A), while S-3066 does not (B).
doi:10.1371/journal.pone.0007150.g005
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pharmacophore, chemical group, or structural feature to explain
binding. Final compounds range in size between 168 and 250
MW, have one to three rings, and a variety of bulky, generally
hydrophobic constituents. But several have charged or polar
groups, no doubt to aid solubility. It is important to realize that the
LOPAC set already have validated drug activities and many are
clinically used for this purpose. Only one general anesthetic is
included in LOPAC, propofol, and it was successfully identified in
this screen. Since general anesthesia is an important side effect that
would be selected against in the development of other drugs, we
did not predict many useful hits in this feasibility screen.
Nevertheless, several candidate compounds were identified for
further testing using receptor or in vivo assays. It is interesting to
note that several compounds have documented activities shared by
some of the existing general anesthetics: inhibition of glutamate,
adrenergic and dopamine receptors, nitric oxide synthase,
monoamine oxidase and various kinases and phosphatases [12].
It is possible that something like general anesthesia is elicited at
concentrations of these compounds higher than needed to produce
their current primary effects.
We validated the final list using isothermal titration calorimetry,
an entirely different and low throughput methodology, to detect
and characterize favorable interactions between two reactants (in
this case, LOPAC compound and apoferritin). Most compounds
showed unambiguous evidence of a favorable interaction, but
several did not. We found that the majority of ITC-negative
compounds were the least soluble, meaning that our saturated
solution did not contain adequate concentrations of compound to
achieve enough occupancy in the apoferritin site to permit
Figure 6. Final compound characteristics and binding summary. Shown are the eighteen compounds, their stick structures and chemical
names. The qHTS IC50 is computed directly from the 1-AMA inhibition data, in molar units, fixing the infinite value to 270%. The ITC KD is derived
from single class fits to enthalpograms (n=1), and is in molar units (NB = no binding). The ITC [compound] column represents the molar
concentration of compound achieved after mixing and filtration prior to loading into ITC syringe. Target concentration was 1 mM in each case, but
clearly not achieved in all. Compound concentrations were measured with UV absorbance.
doi:10.1371/journal.pone.0007150.g006
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experiment only achieves a compound concentration of about
17% of the saturated concentration in the syringe (see Figure 6).
Furthermore, the DMSO included in the qHTS assay may have
increased compound concentration to the point where 1-AMA
displacement could be observed. Such co-solvents are typically not
included in ITC experiments because of extreme dilution heats if
the buffers are not precisely matched. Further prosecution of such
compounds is not warranted as very hydrophobic compounds tend
to be poor anesthetics [6], a phenomenon generically related to the
cut-off effect [13]. At the same time, more soluble compounds tend
to be low affinity anesthetics, thus expanding the screen to increase
compound concentrations (by delivering double the amount of
compound via two successive pin transfers) is not considered a
productive strategy.
In summary, we have developed and tested the feasibility of a
quantitative high throughput assay of a general anesthetic protein
binding site. This initial screen of the LOPAC
1280 library of
compounds demonstrates that the 1-AMA/apoferritin assay can
be used in miniaturized high-throughput screening mode, and sets
the stage for screens of large-size compound libraries. A high rate
of false positives can be addressed through simple filters to achieve
an overall hit rate of about 1% of a validated drug library.
Refinements in screening methodology and post-screening triaging
is expected to further limit the yield of false positives.
Methods
Materials
1-AMA and horse spleen apoferritin were obtained from Sigma
and used without further purification. Dimethyl sulfoxide (DMSO,
certified ACS grade) was from Fisher, Inc. The Library of
Pharmacologically Active Compounds (LOPAC1280, Sigma-
Aldrich) was received as a set of 10 mM DMSO solutions and
formatted in 1,536-well compound plates as a dilution series [7].
Preliminary studies showed only a modest reduction in 1-AMA/
apoferritin signal intensity (,10%) at the maximal expected
DMSO concentration of 1%. Medium binding black solid-bottom
1,536-well plates (assay plates), and 1,536-well polypropylene
plates (compound plates) were purchased from Greiner Bio One
(Monroe, NC).
Screening
Three mL of reagents (free 1-AMA (50% saturated solution of 1-
aminoanthracene in PBS) in columns 3,4 as negative control and
1-AMA/apoferritin mixture (10 mM apoferritin in 50% saturated
1-aminoanthracene in PBS (,15 mM)) in columns 1, 2, 5–48) were
dispensed into 1,536-well Greiner black assay plates. Compounds
(23 nL) were transferred via Kalypsys pintool equipped with
1,536-pin array (10 nL slotted pins, V&P Scientific, San Diego,
CA). The plates were incubated for 10 min at room temperature,
and then read on a ViewLux high-throughput CCD imager
(Perkin-Elmer, Waltham, MA) using standard UV excitation filter
(340 nm, bandwidth 60 nm) and fluorescein emission filter
(540 nm, bandwidth 25 nm). Throughout the screen, reagent
bottles and all liquid lines were made light-tight to minimize
reagent degradation. Activity was computed as the normalized
fluorescence response relative to free 1-AMA and 1-AMA/
apoferritin complex values. Concentration–effect relationships
were derived by using publicly-available curve-fitting algorithms
developed in-house (http://ncgc.nih.gov/pub/openhts/). A four
parameter Hill equation was fitted to the concentration-response
data by minimizing the residual error between the modeled and
observed responses. Compounds were classified as either active
inhibitor, active activator, inconclusive or inactive as described in
the results.
Data filtering
Compounds showing enhancement of signal intensity are
assumed to represent either fluorescence interference or aggrega-
tion phenomena. Thus, for this assay, hits were defined as only
those that showed inhibition of signal intensity, comprising
complete or partial concentration response curves (CRCs). These
hits were then further truncated through the use of two
Figure 7. Relationship between qHTS IC50 and ITC KD. Shown are
13 compounds for which ITC experiments provided reliable parameters,
together with the fit (solid line, R
2=0.4; P=0.02) and the line of identity
(dotted).
doi:10.1371/journal.pone.0007150.g007
Figure 8. Filter performance. Applying screening criteria to both the
inhibitor and inactive groups recovered 21/206 and 157/910 com-
pounds respectively. In each of these filtered groups, the mean and
range for molecular weight, polar surface area (PSA) and octanol/water
partition coefficient (ALogP) are shown. While the inhibitor compounds
are significantly more hydrophobic, as suggested by the higher mean
ALogP (**, P,0.005), the overlap is large and illustrates that the filters
alone provide insufficient discrimination.
doi:10.1371/journal.pone.0007150.g008
General Anesthetic Discovery
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with respect to size and physicochemical character, is well known
[5], we eliminated any compounds larger than 250 Da, and any
with ALogP values outside the range of 1–4. Clinically used
general anesthetics are all consistent with these filters.
Isothermal Titration Calorimetry (ITC)
The filtered compound list was then subjected to a secondary
validation using a direct binding technology, isothermal titration
calorimetry (ITC) (MicroCal VP-ITC, Northampton, MA).
Compounds were obtained directly from Sigma, Altan, Tocris or
Acros, and ,1 mM solutions were prepared in a phosphate
buffered saline (PBS). This was accomplished through vigorous
shaking and sonication of the solution, followed by filtration
through 0.2 mm PTFE syringe filters. Concentrations were then
confirmed with absorption spectroscopy. Several compounds were
found to be far less soluble in aqueous buffer than 1 mM, limiting
the ability of ITC to determine binding (see below). The ITC cell
was loaded with 2.5 mg/ml apoferritin, and the syringe loaded
with the compound solution. Titrations were conducted at 20uC,
subtracted by buffer to buffer and compound to buffer runs, and
the enthalpograms fitted to a single class binding site model using
Origin 7.0. Each compound was run in duplicate.
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